Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CLVS message board posts where the ticker symbol CLVS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CLVS SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-028344 Size: 4 KB
2017-12-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-027813 Size: 8 KB
2017-12-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-027812 Size: 8 KB
2017-12-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-026604 Size: 5 KB
2017-11-16
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-17-008019 (34 Act)  Size: 7 MB
2017-11-02 001-35347
171172920
8-K  Documents Current report, item 3.02
Acc-no: 0001193125-17-330967 (34 Act)  Size: 14 KB
2017-11-02 001-35347
171172271
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001157523-17-002944 (34 Act)  Size: 122 KB
2017-11-01 001-35347
171169347
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-024388 Size: 5 KB
2017-10-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-022210 Size: 5 KB
2017-09-18
4/A  Documents [Amend] Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-021361 Size: 5 KB
2017-09-01
More CLVS SEC Filings


Related news from
Wed, 06 Dec 2017
20:09:08 +0000
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Wed, 06 Dec 2017
19:08:47 +0000
Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.
Wed, 06 Dec 2017
14:30:00 +0000
Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
Wed, 06 Dec 2017
12:46:12 +0000
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
Wed, 06 Dec 2017
01:25:11 +0000
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018, Clovis announced Tuesday.
Tue, 05 Dec 2017
21:05:00 +0000
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
Clovis Oncology announced today that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act date of April 6, 2018.
Tue, 28 Nov 2017
16:58:00 +0000
Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte
After a very strong year, the biotech sector has suffered an 8% pullback over the past 5 weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro, and Incyte.
Mon, 27 Nov 2017
13:04:24 +0000
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.97 billion over the last one-month into ETFs that hold CLVS are not among the highest of the last year and have been slowing.
Fri, 24 Nov 2017
16:24:04 +0000
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Tue, 21 Nov 2017
15:25:03 +0000
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
Mon, 20 Nov 2017
13:20:00 +0000
Today’s Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology
NEW YORK, NY / ACCESSWIRE / November 20, 2017 / U.S. markets closed in the red Friday, with the Dow Jones and S&P 500 posting their second consecutive weekly loss, as concerns regarding President Trump's ...
Tue, 14 Nov 2017
19:55:43 +0000
CORRECTING and REPLACING – Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 14, 2017-- In a release issued under the same headline on November 13th, 2017 by Fundamental Markets, please note that in the P ure Storage's Recent Financial Performance section, the first ...
Mon, 13 Nov 2017
23:45:54 +0000
Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT
Q3 2017 Clovis Oncology Inc Earnings Call
Mon, 13 Nov 2017
12:50:00 +0000
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 13, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pure ...
Wed, 08 Nov 2017
23:40:00 +0000
Clovis Oncology to Present at the Stifel 2017 Healthcare Conference
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 AM Eastern Time.
Wed, 08 Nov 2017
18:45:39 +0000
Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Wed, 08 Nov 2017
12:40:00 +0000
Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab
Research Desk Line-up: Clovis Oncology Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Wed, 01 Nov 2017
20:05:00 +0000
Clovis Oncology Announces Third Quarter 2017 Operating Results
Clovis Oncology, Inc. reported financial results for the quarter ended September 30, 2017, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2017.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is the gold standard, valuable because of the exceptional people who post here, and because the best of them are candid, detailed and informed. There is little tolerance for the b.s. found on public boards, and management and members are vigilant and aggressive about TOS violations. VF is the gold standard." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards